Lobbying Information
Subject Matters
- Budget
- Health
- Industry
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Grant, Contribution or Other Financial Benefit
- Advocating for an increase in targeted research funding for ALS. Sources of funding are to be determined.
- To provide funding for neuromuscular diseases, one of which is ALS, with regards to reinstating funding from the government to help fund researchers in the neuromuscular field. Sources of funding are to be determined.
Policies or Program
- Amendment to the compassionate care program to make it more accessible to caregivers and to increase the length of the benefit.
- Policies or programs related to access to care and potential treatments for the ALS Community.
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Canadian Institutes of Health Research (CIHR)
-
Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC)
-
Employment and Social Development Canada (ESDC)
-
Finance Canada (FIN)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Natural Resources Canada (NRCan)
-
Prime Minister's Office (PMO)
-
Public Health Agency of Canada (PHAC)
-
Senate of Canada
In-house Organization Details
Description of the organization's activities
The Amyotrophic Lateral Sclerosis Society of Canada, founded in 1977, is the only national voluntary health organization dedicated solely to the fight against ALS, and support for those living with ALS. ALS Canada funds research towards a treatment for ALS, supports our federation member societies in the provision of quality care for those living with ALS, and provides information to build awareness about the disease. The vision of the ALS Society of Canada is to find a cure for ALS. ALS, more commonly known as Lou Gehrig's disease, is a rapidly progressive and fatal neuromuscular disorder that causes the degeneration of a select group of nerve cells in the brain and spinal cord. As the nerve cells die, people with ALS lose control of their muscles, which makes breathing, eating and even smiling almost impossible. Approximately 2,500 - 3,000 Canadians currently live with ALS.
Responsible officer name and position during the period of this registration
Tammy Moore,
Chief Executive Officer
Organization's membership or classes of membership
ALS Canada operates within a federated model with representation from the 10 provinces, which provides a framework through which the partners work together and share resources. ALS Canada works with the provincial member societies to provide care to those affected by ALS, and to help fulfill our vision to find effective treatments and eventually a cure for this devastating disease. ALS Canada does not have members or classes of members.
Government funding
No government funding was received during the last completed financial year.
In-house Organization Contact Information
Address:
393 University Avenue, Suite 1701
Toronto, ON M5G 1E6
Canada
Telephone number:
416-497-2267
Ext.
201
Lobbyists Details
Employees who lobby for the organization
- Lisa Marchitto,
Vice President of Marketing and Public Affairs |
No public offices held
- Tammy Moore,
Chief Executive Officer |
No public offices held
- Lauren Poplak,
Manager, Public Affairs |
No public offices held
- David Taylor,
Vice President, Research |
No public offices held
